What is Lifesci Capital’s Estimate for LRMR Q2 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at Lifesci Capital issued their Q2 2025 earnings per share estimates for Larimar Therapeutics in a report released on Monday, June 23rd. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.46) per share for the quarter. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q3 2025 earnings at ($0.46) EPS and Q4 2025 earnings at ($0.46) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Other analysts also recently issued research reports about the company. Wedbush dropped their price objective on Larimar Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday. Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. HC Wainwright boosted their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Finally, Robert W. Baird lowered their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Larimar Therapeutics presently has an average rating of “Buy” and an average price target of $18.50.

Larimar Therapeutics Trading Up 8.7%

Shares of Larimar Therapeutics stock opened at $3.25 on Wednesday. The company has a market capitalization of $208.10 million, a PE ratio of -2.18 and a beta of 0.79. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $11.20. The stock’s fifty day simple moving average is $2.37 and its 200 day simple moving average is $2.96.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in Larimar Therapeutics during the fourth quarter valued at approximately $25,000. Walleye Capital LLC acquired a new position in shares of Larimar Therapeutics during the first quarter worth $37,000. Algert Global LLC acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $47,000. Graham Capital Management L.P. acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $54,000. Finally, ProShare Advisors LLC acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $58,000. 91.92% of the stock is currently owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.